This post was originally published on this site
AFP via Getty Images
Stock-index futures were mixed Friday as rising COVID-19 cases raise doubts about the prospects for the economic recovery, offset partly by optimism over prospects for vaccines.
The Treasury Department’s decision to allow emergency Federal Reserve programs expire, however, were a potential negative, analysts said.
What are major benchmarks doing?
- Futures on the Dow Jones Industrial Average YM00 fell 45 points, or 0.2%, to 29,398.
- S&P 500 futures ES00, -0.10% were off 1.60 points, or less than 0.1%, at 3,578.50.
- Nasdaq-100 futures NQ00, +0.15% rose 24.25 points, or 0.2%, to 12,011.50.
Stocks eked out gains in a choppy trading session on Thursday:
- The Dow DJIA, +0.15% rose 44.81 points, or 0.2%, to close at 29,483.23.
- The S&P 500 SPX, +0.39% gained 14.08 points, or 0.4%, to finish at 3,581.87.
- The Nasdaq Composite COMP, +0.87% ended at 11,904.71, a rise of 103.11 points, or 0.9%.
What’s driving the market?
Stocks have seen choppy trade this week as investors weighed optimism over progress toward COVID-19 vaccines against a continued surge in new infections.
“The strains from COVID are hitting medical systems in the Midwest and it is almost certain that mobility is down and will likely remain that through the holiday shopping season,” said Boris Schlossberg, managing director at BK Asset Management, in a note.
“That will be positive for digital retailers but may be the death knell for many small to medium-size brick and mortar stores and will likely create further contractionary ripples in the economy in Q4,” he said.
Markets have been buoyed, however, as drugmakers make rapid progress toward a vaccine, he said.
Pfizer Inc. PFE, -0.35% on Friday said it would file Friday for approval from U.S. regulators for emergency use of the vaccine it’s developed with BioNTech SE BNTX, +4.96% that has proven 95% effective in a clinical trial. Moderna Inc. MRNA, +4.36% earlier this week said its vaccine candidate was more than 94% effective.
Meanwhile, analysts said a rift between the Treasury Department and the Federal Reserve was another negative for the market. Treasury Secretary Steven Mnuchin said he wouldn’t approve the extension of several emergency loan programs set up with the Fed during the worst days of the financial turmoil created by the pandemic earlier this year.
The Fed responded that it “would prefer that the full suite of emergency facilities established during the coronavirus pandemic continue to serve their important role as a backstop for our still-strained and vulnerable economy.”
Need to Know: What’s next for markets after Treasury Secretary Steven Mnuchin pulls the $455 billion plug
“The emergency lending facilities have been little-used, but their existence has been key in ensuring a credible safeguard against financial market stress,” said Gregory Daco, chief U.S. economist at Oxford Economics, in a note.
“With the Covid-19 crisis worsening and activity slowing in the absence of fiscal aid, the decision to curtail the Fed’s firepower could unsettle markets and exacerbate economic stress,” he said.
Which companies are in focus?
- Shares of Gilead Sciences Inc. GILD, -0.44% fell 1.8% after a World Health Organization panel recommended against doctors using the drug remdesivir to treat coronavirus patients.
- Shares of Workday Inc. WDAY, +3.21% were down 2% in premarket trade after the cloud software company delivered strong revenue and continued earnings growth in its third-quarter results.
- Shares of software-security company McAfee Inc. MCFE, -1.20% could be in focus after it reported a break-even third quarter on sales of $728 million, delivering its first results since returning to public markets last month.
- Foot Locker Inc. FL, +3.48% shares were 4% higher in premarket trade after the athletic shoe and accessories seller reported a surprise increase in same-store sales and profit that rose well above expectations.
